Ones To Watch News
Refine Search
Pharmaceutical
Dutch specialist development pharma, Amzell has signed a license and development agreement with Amring Pharmaceuticals, a subsidiary of SEVER Life, for the commercial rights to one of its leading clinical-stage candidates. 31 March 2021
Biotechnology
Just two weeks after announcing a worldwide licensing agreement with Pfizer to develop and commercialize multiple antibody drug conjugates, Pyxis Oncology has announced a $152 million Series B financing. 30 March 2021
Pharmaceutical
Dutch specialist pharmaceutical development company Amzell has acquired Bazell Pharma, a high-end clinical development and R&D laboratory facility based in Allschwil, Switzerland, to help to accelerate its development pipeline of late-stage novel drug candidates. 25 March 2021
Biotechnology
Californian aging specialist CohBar is using mitochondrial science to treat diseases, but chief executive Steven Engle doesn’t rule out offering a “cure for ageing” at some point. 23 March 2021
Biotechnology
US oral peptides specialist Chiasma’s shares were up 13% at $3.89 pre-market today, after the company announced the presentation of new positive clinical data from its MPOWERED Phase III trial of Mycapssa (octreotide) at the Endocrine Society’s annual meeting, ENDO 2021, being held virtually March 20-23, 2021. 23 March 2021
Biotechnology
US biotech VistaGen Therapeutics has presented data highlighting the proposed mechanism of action (MOA) of its Phase III investigational drug candidate, PH94B nasal spray at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. 22 March 2021
Biotechnology
Germany-based biotech Evotec has entered into a multi-RNA target alliance with Takeda Pharmaceutical with the aim of discovering and developing RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. 22 March 2021
Biotechnology
The US Food and Drug Administration has approved Arcalyst (rilonacept) injection to treat recurrent pericarditis and reduce the risk of recurrence in adults and children 12 years and older. 19 March 2021
Biotechnology
Canadian biopharma company and UK pharma major GlaxoSmithKline have started Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. 16 March 2021
Biotechnology
Perception Neuroscience, a platform company of German biotech atai Life Sciences and Japan’s Otsuka have signed a collaboration and licensing agreement for the development and commercialization of Perception’s lead molecule, PCN-101 (arketamine) in Japan as a potential treatment for mood disorders such as major depressive disorder (MDD) and treatment-resistant depression (TRD). 16 March 2021
Biotechnology
USA and Canada-based biotech CytoDyn, which is developing Vyrologix (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, yesterday reported the Phase III trial of leronlimab for the treatment of severe-to-critical patients with COVID-19. 9 March 2021
Pharmaceutical
Swiss drugmaker Vifor Pharma and Cara Therapeutics today announced that the US Food and Drug Administration has accepted and granted Priority Review for the New Drug Application (NDA) for Korsuva (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. 8 March 2021
Biotechnology
US pharma giant Merck & Co and privately-held biotech Ridgeback Biotherapeutics today announced encouraging preliminary results from Ridgeback’s Phase IIa randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir (EIDD-2801/MK-4482), an investigational oral antiviral agent. 8 March 2021
Biotechnology
The USA’s largest biotech firm Amgen, which has been fairly quiet on the M&A front for a while, announced it was splashing out nearly $2 billion on an acquisition today. 4 March 2021
Pharmaceutical
UK-based Autifony Therapeutics, which is pioneering the development of novel pharmaceutical treatments for serious nervous system disorders, including schizophrenia, hearing loss, Fragile X syndrome and amyotrophic lateral sclerosis, today announced a new collaboration with family-owned German pharma major Boehringer Ingelheim. 4 March 2021
Biotechnology
US oncology drug developer G1 Therapeutics and German family-owned pharma major Boehringer Ingelheim today announced that Cosela (trilaciclib) for injection is now available in the USA. 2 March 2021
Pharmaceutical
The US Food and Drug Administration on Friday approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to molybdenum cofactor deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death. 1 March 2021
Biotechnology
The US Food and Drug Administration has granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. 26 February 2021
Biotechnology
US biotech Pandion Therapeutics’ shares rocketed 133% to $59.63 in morning trading, after it was revealed that it has agreed to be acquired by US pharma giant Merck & Co. 25 February 2021
Biotechnology
US biotech Scynexis has partnered with Amplity Health in connection with the anticipated US launch of Brexafemme (ibrexafungerp). 24 February 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze